Longeveron (NASDAQ:LGVN) Downgraded by Wall Street Zen to Sell

Longeveron (NASDAQ:LGVN) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings downgraded shares of Longeveron from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, September 8th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $80.00.

Longeveron Price Performance

NASDAQ LGVN opened at $2.49 on Friday. Longeveron has a 1 year low of $1.31 and a 1 year high of $12.30. The firm has a market cap of $7.94 million, a price-to-earnings ratio of -0.31 and a beta of -0.09. The company has a fifty day moving average price of $2.92 and a 200-day moving average price of $6.44.

Longeveron (NASDAQ:LGVN) last announced its earnings results on Thursday, November 12th. The company reported ($1.91) EPS for the quarter, missing the consensus estimate of ($1.70) by ($0.21). Longeveron had a negative net margin of 1,921.72% and a negative return on equity of 209.21%. The firm had revenue of $0.12 million during the quarter, compared to analysts’ expectations of $0.80 million. On average, research analysts anticipate that Longeveron will post -7.20 EPS for the current fiscal year.

Institutional Investors Weigh In On Longeveron

A hedge fund recently bought a new position in Longeveron stock. ADAR1 Capital Management LLC purchased a new stake in shares of Longeveron Inc. (NASDAQ:LGVN) in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 200,000 shares of the company’s stock, valued at approximately $208,000. ADAR1 Capital Management LLC owned 0.86% of Longeveron as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 10.01% of the company’s stock.

About Longeveron

Longeveron Inc. is a clinical-stage biotechnology company focused on developing regenerative medicines for serious and life-threatening conditions. The company’s research centers on cell-based therapies intended to support tissue repair, reduce harmful inflammation and promote the body’s natural healing processes. Longeveron’s lead investigational product is Lomecel-B, an allogeneic cell therapy derived from bone marrow obtained from healthy adult donors. The company has evaluated Lomecel-B in clinical programs addressing hypoplastic left heart syndrome, a rare congenital heart defect in infants, as well as Alzheimer’s disease and aging-related frailty.